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OBJECTIVES: Long-acting insulin analogs, such as insulin
glargine, offer the promise of better glycemic control, reduced
risk of complications, and moderation of health care use and
costs in patients with diabetes. We studied initiation of insulin
glargine to evaluate its association with changes in clinical mea-
sures and subsequent health care utilization and expenditures.
METHODS: U.S. Veterans Health Administration (VA) patients
who initiated insulin glargine (N = 5,057) in 2001 or 2002 were
compared to a sample of diabetes patients continuing to receive
other insulin (N = 69,940), matched on month of prescription
(index date). Hemoglobin A1c (HgA1c), hypoglycemia rates, and
VA health care (inpatient and outpatient) in the 12 months after
a patient’s index date were compared. Utilization differences
were evaluated using Tobit regression and other differences using
linear and logistic regression, controlling for prior utilization,
demographics, co-morbidities, and diabetes severity. National
average utilization and pharmacy costs were used to estimate
value of VA expenditures. RESULTS: Insulin glargine initiators
were younger (59 vs. 65 years) than other insulin users with more
diabetes complications and more intensive medication manage-
ment. They had higher HgA1c (8.7% vs. 8.1%) and hypo-
glycemia rates (11.5% vs. 4.4%) prior to the index date, but
greater subsequent reductions (HgA1c: -0.50% vs.-0.24%;
hypoglycemia: -5.0% vs.-1.3%). Insulin glargine initiation was
associated with 2.4 (95% CI: 1.1–3.7) fewer inpatient days for
patients with any hospitalization (lower cost of $820 per initia-
tor). This more than offset the higher costs of more outpatient
encounters (1.6 (1.2–1.9) or $229 per initiator) and higher med-
ication costs ($347 ($337–$356) per initiator). CONCLUSION:
Insulin glargine use was associated with improvements in
glycemic control, hypoglycemia rates, and utilization expendi-
tures. We conclude that insulin glargine use may improve 
management of diabetes patients leading to reduced risk of 
complications and less time in hospital with no net increase in
cost.
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OBJECTIVES: This study compares the effect of two injectable
therapies, exenatide and insulin glargine, on quality of life mea-
surements in patients with Type-2 diabetes inadequately con-
trolled on oral antidiabetic medications. Previous research has
shown that increasing treatment complexity results in a negative
impact on patient reported outcomes. As exenatide and insulin
glargine are both adjunctive to pre-existing oral therapy in this
study, the impact on quality of life from adding an injectable
therapy is examined. Additionally, differences in quality of life
between the medications are examined. METHODS: Patients
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